129 related articles for article (PubMed ID: 15486557)
1. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter.
Jacob D; Davis JJ; Zhang L; Zhu H; Teraishi F; Fang B
Cancer Gene Ther; 2005 Feb; 12(2):109-15. PubMed ID: 15486557
[TBL] [Abstract][Full Text] [Related]
2. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
[TBL] [Abstract][Full Text] [Related]
3. [Adenoviral vector expressing the TRAIL gene driven by the hTERT promoter].
Jacob D; Davis J; Schumacher G; Bahra M; Neuhaus P; Fang B
Z Gastroenterol; 2004 Dec; 42(12):1363-70. PubMed ID: 15592959
[TBL] [Abstract][Full Text] [Related]
4. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells.
Jacob D; Schumacher G; Bahra M; Davis J; Zhu HB; Zhang LD; Teraishi F; Neuhaus P; Fang BL
World J Gastroenterol; 2005 May; 11(17):2552-6. PubMed ID: 15849810
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy in colon cancer cells with a fiber-modified adenovector expressing the TRAIL gene driven by the hTERT promoter.
Jacob D; Bahra M; Schumacher G; Neuhaus P; Fang B
Anticancer Res; 2004; 24(5A):3075-9. PubMed ID: 15517918
[TBL] [Abstract][Full Text] [Related]
6. Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer.
Wack S; Rejiba S; Parmentier C; Aprahamian M; Hajri A
Mol Ther; 2008 Feb; 16(2):252-60. PubMed ID: 17984977
[TBL] [Abstract][Full Text] [Related]
7. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes.
Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B
Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter.
Katz MH; Spivack DE; Takimoto S; Fang B; Burton DW; Moossa AR; Hoffman RM; Bouvet M
Ann Surg Oncol; 2003 Aug; 10(7):762-72. PubMed ID: 12900367
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.
Zhang X; Cheung RM; Komaki R; Fang B; Chang JY
Clin Cancer Res; 2005 Sep; 11(18):6657-68. PubMed ID: 16166445
[TBL] [Abstract][Full Text] [Related]
10. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S
Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092
[TBL] [Abstract][Full Text] [Related]
11. The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells.
Choi E; Kim Y; Kim K
Yonsei Med J; 2006 Feb; 47(1):55-62. PubMed ID: 16502485
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
13. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer.
Murugesan SR; King CR; Osborn R; Fairweather WR; O'Reilly EM; Thornton MO; Wei LL
Cancer Gene Ther; 2009 Nov; 16(11):841-7. PubMed ID: 19444305
[TBL] [Abstract][Full Text] [Related]
14. [Killing effect of Ad.TERT-TRAIL on tumor cell lines and its mechanism].
Tang YX; Chen Y; Gu JF; Qi R; Zou WG; Jiang LL; Liu XY
Ai Zheng; 2005 May; 24(5):536-42. PubMed ID: 15890093
[TBL] [Abstract][Full Text] [Related]
15. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
Dong F; Wang L; Davis JJ; Hu W; Zhang L; Guo W; Teraishi F; Ji L; Fang B
Clin Cancer Res; 2006 Sep; 12(17):5224-30. PubMed ID: 16951242
[TBL] [Abstract][Full Text] [Related]
16. [Effects of human telomerase reverse transcriptase promoter and survivin promoter in targeted tumor gene therapy].
Zhang Y; Ma H; Liu SL; Liu YX; Zheng DX
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(7):475-9. PubMed ID: 18642790
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Ibrahim SM; Ringel J; Schmidt C; Ringel B; Müller P; Koczan D; Thiesen HJ; Löhr M
Pancreas; 2001 Jul; 23(1):72-9. PubMed ID: 11451151
[TBL] [Abstract][Full Text] [Related]
18. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
19. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
[TBL] [Abstract][Full Text] [Related]
20. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
